A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Lung cancer switch does the job for Black Diamond
First data with the biotech’s new EGFR project prompts a 236% share price bump.
